{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:23:16Z","timestamp":1740144196490,"version":"3.37.3"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T00:00:00Z","timestamp":1604016000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T00:00:00Z","timestamp":1604016000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100009530","name":"Jawaharlal Institute Of Postgraduate Medical Education and Research","doi-asserted-by":"publisher","award":["JIP\/Res\/Intra-MD\/MS\/01\/2014","JIP\/Res\/Intra-MD,MS\/sec\/05\/2014"],"award-info":[{"award-number":["JIP\/Res\/Intra-MD\/MS\/01\/2014","JIP\/Res\/Intra-MD,MS\/sec\/05\/2014"]}],"id":[{"id":"10.13039\/501100009530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s12282-020-01177-x","type":"journal-article","created":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T16:06:53Z","timestamp":1604074013000},"page":"414-423","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Association of plasma docetaxel levels with ABCB1 gene polymorphisms and tumour response in locally advanced breast cancer patients of South India on neo\u2010adjuvant chemotherapy"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7934-4978","authenticated-orcid":false,"given":"Rekha","family":"Priyadarshini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7499-7219","authenticated-orcid":false,"given":"Gerard Marshall","family":"Raj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajan","family":"Sundaram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7275-7377","authenticated-orcid":false,"given":"Smita","family":"Kayal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ananthakrishnan","family":"Ramesh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9993-6551","authenticated-orcid":false,"given":"Deepak Gopal","family":"Shewade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,10,30]]},"reference":[{"key":"1177_CR1","first-page":"CD003366","volume":"2015","author":"D Ghersi","year":"2015","unstructured":"Ghersi D, Willson ML, Chan MMK, Simes J, Donoghue E, Wilcken N. Taxane-containing regimens for metastatic breast cancer. Cochrane Database Syst Rev. 2015;2015:CD003366.","journal-title":"Cochrane Database Syst Rev"},{"key":"1177_CR2","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/cam4.985","volume":"6","author":"LY Lim","year":"2017","unstructured":"Lim LY, Miao H, Lim JSJ, Lee SC, Bhoo-Pathy N, Yip CH, et al. Outcome after neoadjuvant chemotherapy in Asian breast cancer patients. Cancer Med. 2017;6:173\u201385.","journal-title":"Cancer Med"},{"key":"1177_CR3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1023\/A:1024333725148","volume":"79","author":"AW Hutcheon","year":"2003","unstructured":"Hutcheon AW, Heys SD, Sarkar TK, Aberdeen Breast Group. Neoadjuvant docetaxel in locally advanced breast cancer. Breast Cancer Res Treat. 2003;79:19\u201324.","journal-title":"Breast Cancer Res Treat"},{"key":"1177_CR4","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.7314\/APJCP.2014.15.5.1989","volume":"15","author":"A Gogia","year":"2014","unstructured":"Gogia A, Raina V, Deo SV, Shukla NK, Mohanti BK, Sharma DN. Taxane and anthracycline based neoadjuvant chemotherapy for locally advanced breast cancer: institutional experience. Asian Pac J Cancer Prev. 2014;15:1989\u201392.","journal-title":"Asian Pac J Cancer Prev"},{"key":"1177_CR5","unstructured":"NCCN Clinical Practice Guidelines in Oncology [Internet]. 2019 [cited 2020 Sep 10]. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf."},{"key":"1177_CR6","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.ctrv.2015.04.012","volume":"41","author":"AJM Nieuweboer","year":"2015","unstructured":"Nieuweboer AJM, de Morre ES, de Graan AJM, Sparreboom A, de Wit R, Mathijssen RHJ. Inter-patient variability in docetaxel pharmacokinetics: a review. Cancer Treat Rev. 2015;41:605\u201313.","journal-title":"Cancer Treat Rev"},{"key":"1177_CR7","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1097\/FPC.0b013e3283335277","volume":"19","author":"C Oshiro","year":"2009","unstructured":"Oshiro C, Marsh S, McLeod H, Carrillo MW, Klein T, Altman R. Taxane pathway. Pharmacogenet Genomics. 2009;19:979\u201383.","journal-title":"Pharmacogenet Genomics"},{"key":"1177_CR8","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1111\/jcpt.12797","volume":"44","author":"R Priyadarshini","year":"2019","unstructured":"Priyadarshini R, Raj GM, Kayal S, Ramesh A, Shewade DG. Influence of ABCB1 C3435T and C1236T gene polymorphisms on tumour response to docetaxel-based neo-adjuvant chemotherapy in locally advanced breast cancer patients of South India. J Clin Pharm Ther. 2019;44:188\u201396.","journal-title":"J Clin Pharm Ther"},{"key":"1177_CR9","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s40262-015-0267-1","volume":"54","author":"S Wolking","year":"2015","unstructured":"Wolking S, Schaeffeler E, Lerche H, Schwab M, Nies AT. Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: update of the Literature. Clin Pharmacokinet. 2015;54:709\u201335.","journal-title":"Clin Pharmacokinet"},{"key":"1177_CR10","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1080\/03602532.2016.1226896","volume":"48","author":"S Chen","year":"2016","unstructured":"Chen S, Sutiman N, Zhang CZ, Yu Y, Lam S, Khor CC, et al. Pharmacogenetics of irinotecan, doxorubicin and docetaxel transporters in Asian and Caucasian cancer patients: a comparative review. Drug Metab Rev. 2016;48:502\u201340.","journal-title":"Drug Metab Rev"},{"key":"1177_CR11","first-page":"589","volume-title":"American Joint Committee on Cancer. AJCC Cancer Staging Manual","author":"GN Hortobagyi","year":"2018","unstructured":"Hortobagyi GN, Connolly JL, D\u2019Orsi CJ, Edge SB, Mittendorf EA, Rugo HS, et al. Breast. In: Amin MB, Edge SB, Greene F, Byrd DR, Brookland RK, Wasinghton MK, et al., editors. American Joint Committee on Cancer. AJCC Cancer Staging Manual. 8th ed. New York: Springer; 2018. p. 589\u2013636.","edition":"8"},{"key":"1177_CR12","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s10549-013-2545-7","volume":"139","author":"P L\u00e9vy","year":"2013","unstructured":"L\u00e9vy P, Gligorov J, Antoine M, Rezai K, L\u00e9vy E, Selleet F, et al. Influence of ABCB1 polymorphisms and docetaxel pharmacokinetics on pathological response to neoadjuvant chemotherapy in breast cancer patients. Breast Cancer Res Treat. 2013;139:421\u20138.","journal-title":"Breast Cancer Res Treat"},{"key":"1177_CR13","unstructured":"Jones J, Denbigh J. LC-MS\/MS Method for the Determination of Docetaxel in Human Serum for Clinical Research. In: Thermoscientific Application Note 20581 [Internet]. 2012 [cited 2020 Sep 10]. https:\/\/www.separatedbyexperience.com\/documents\/AN20581_E_08-12S_v8.pdf."},{"key":"1177_CR14","doi-asserted-by":"crossref","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al.. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer Oxf Engl 2009;45:228\u2013247.","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"1177_CR15","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2165\/00003088-199936020-00002","volume":"36","author":"SJ Clarke","year":"1999","unstructured":"Clarke SJ, Rivory LP. Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet. 1999;36:99\u2013114.","journal-title":"Clin Pharmacokinet"},{"key":"1177_CR16","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.canlet.2015.10.010","volume":"370","author":"Z Chen","year":"2016","unstructured":"Chen Z, Shi T, Zhang L, Zhu P, Deng M, Huang C, et al. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: a review of the past decade. Cancer Lett. 2016;370:153\u201364.","journal-title":"Cancer Lett"},{"key":"1177_CR17","doi-asserted-by":"publisher","first-page":"5786","DOI":"10.1158\/1078-0432.CCR-05-2649","volume":"12","author":"TM Bosch","year":"2006","unstructured":"Bosch TM, Huitema ADR, Doodeman VD, Jansen R, Witteveen E, Smit WM, et al. Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel. Clin Cancer Res. 2006;12:5786\u201393.","journal-title":"Clin Cancer Res"},{"key":"1177_CR18","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1136\/ijgc-00009577-200605000-00004","volume":"16","author":"H Yamaguchi","year":"2006","unstructured":"Yamaguchi H, Hishinuma T, Endo N, Tsukamoto H, Kishikawa Y, Sato M, et al. Genetic variation in ABCB1 influences paclitaxel pharmacokinetics in Japanese patients with ovarian cancer. Int J Gynecol Cancer. 2006;16:979\u201385.","journal-title":"Int J Gynecol Cancer"},{"key":"1177_CR19","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/sj.bjc.6605789","volume":"103","author":"A Fajac","year":"2010","unstructured":"Fajac A, Gligorov J, Rezai K, L\u00e9vy P, L\u00e9vy E, Selle F, et al. Effect of ABCB1 C3435T polymorphism on docetaxel pharmacokinetics according to menopausal status in breast cancer patients. Br J Cancer. 2010;103:560\u20136.","journal-title":"Br J Cancer"},{"key":"1177_CR20","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/cas.12560","volume":"106","author":"H-J Kim","year":"2015","unstructured":"Kim H-J, Im S-A, Keam B, Ham HS, Lee KH, Kim TY, et al. ABCB1 polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapy. Cancer Sci. 2015;106:86\u201393.","journal-title":"Cancer Sci"},{"key":"1177_CR21","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s00228-016-2031-3","volume":"72","author":"H Onoue","year":"2016","unstructured":"Onoue H, Yano I, Tanaka A, Itohara K, Hanai A, Ishiguro H, et al. Significant effect of age on docetaxel pharmacokinetics in Japanese female breast cancer patients by using the population modeling approach. Eur J Clin Pharmacol. 2016;72:703\u201310.","journal-title":"Eur J Clin Pharmacol"},{"key":"1177_CR22","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/clpt.2008.95","volume":"85","author":"SD Baker","year":"2009","unstructured":"Baker SD, Verweij J, Cusatis GA, van Schaik RH, Marsh S, Orwick SJ, et al. Pharmacogenetic pathway analysis of docetaxel elimination. Clin Pharmacol Ther. 2009;85:155\u201363.","journal-title":"Clin Pharmacol Ther"},{"key":"1177_CR23","doi-asserted-by":"publisher","first-page":"4543","DOI":"10.1158\/1078-0432.CCR-07-4230","volume":"14","author":"TM Sissung","year":"2008","unstructured":"Sissung TM, Baum CE, Deeken J, Price DK, Aragon-Ching J, Steinberg SM, et al. ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel. Clin Cancer Res. 2008;14:4543\u20139.","journal-title":"Clin Cancer Res"},{"key":"1177_CR24","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1007\/s00280-011-1625-9","volume":"67","author":"SC Chew","year":"2011","unstructured":"Chew SC, Singh O, Chen X, Ramasamy RD, Kulkarni T, Lee EJ, et al. The effects of CYP3A4, CYP3A5, ABCB1, ABCC2, ABCG2 and SLCO1B3 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of docetaxel in nasopharyngeal carcinoma patients. Cancer Chemother Pharmacol. 2011;67:1471\u20138.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1177_CR25","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/tpj.2015.66","volume":"16","author":"AJM Nieuweboer","year":"2016","unstructured":"Nieuweboer AJM, Smid M, Graan A-JM, Elbouazzaoui S, Bruijn P, Eskens FALM, et al. Role of genetic variation in docetaxel-induced neutropenia and pharmacokinetics. Pharmacogenomics J. 2016;16:519\u201324.","journal-title":"Pharmacogenomics J"},{"key":"1177_CR26","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.clpt.2006.02.003","volume":"79","author":"A Tran","year":"2006","unstructured":"Tran A, Jullien V, Alexandre J, Rey E, Rabillon F, Girre V, et al. Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms. Clin Pharmacol Ther. 2006;79:570\u201380.","journal-title":"Clin Pharmacol Ther"},{"key":"1177_CR27","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2147\/PGPM.S86672","volume":"9","author":"B Mittal","year":"2016","unstructured":"Mittal B, Tulsyan S, Mittal R. The effect of ABCB1 polymorphisms on the outcome of breast cancer treatment. Pharmacogenomics Pers Med. 2016;9:47\u20138.","journal-title":"Pharmacogenomics Pers Med"}],"container-title":["Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-020-01177-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12282-020-01177-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-020-01177-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T16:55:57Z","timestamp":1614704157000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12282-020-01177-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,30]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["1177"],"URL":"https:\/\/doi.org\/10.1007\/s12282-020-01177-x","relation":{},"ISSN":["1340-6868","1880-4233"],"issn-type":[{"type":"print","value":"1340-6868"},{"type":"electronic","value":"1880-4233"}],"subject":[],"published":{"date-parts":[[2020,10,30]]},"assertion":[{"value":"10 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee (Institute Ethics Committee (IEC) [No.JIP\/IEC\/SC\/2014\/1\/497] of JIPMER) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"An informed and written consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}